Page advises public companies on capital-raising transactions, SEC reporting and corporate governance. Page also counsels public and private companies on a broad range of executive compensation and equity compensation arrangements and programs, including equity and incentive plans and related tax, corporate, and securities law concerns.

Page concentrates her practice on the life sciences and technology sectors, including representing pharmaceutical, biotech, and medical device companies.

She represents issuers in IPOs, de-SPAC and reverse merger transactions, follow-on public offerings, ATM offerings, registered directs, and PIPEs.  Page also has experience representing buyers and sellers in mergers and acquisitions, spin-offs, and private equity investments. As part of her practice advising public companies, Page helps clients navigate corporate governance and securities compliance obligations, ESG matters, Nasdaq and NYSE listing requirements, proxy advisory firm policies, and rules regarding disclosure of director and executive compensation.

Page also has an active pro bono practice. She has represented clients in applications for political asylum in the United States and represented asylum candidates in bond hearings.